A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Summary

This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).

Timeline

Start

2021-03-02

Primary completion

2028-06-19

Completion

2028-06-19

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “trial of AZD0486, a novel CD19xCD3 T cell engager, showed durable responses in patients with heavily pretreated relapsed/refractory follicular lymphoma” astrazeneca.com ↗

Drugs

Indications